Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.76
(
-1.36%
)
US TECH 100
23,821.20
(
-1.29%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
70,938.44
(
-4.06%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 42539

Tuesday, 02/27/2007 6:10:12 PM

Tuesday, February 27, 2007 6:10:12 PM

Post# of 257253
HGSI Albuferon addendum:

The non-inferiority threshold in the two phase-3 trials is 6% (12% if calculated as two-sided). The trials are powered at 90% to achieve non-inferiority vs Pegasys for at least one of the two Albuferon doses.

The power for showing superiority of at least one dose of Albuferon to Pegasys is closer to 80%.

Source: Today’s CC

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now